Request Speaker Information
Speakers and Panels
Beyond the Building: Creating Campuses Where Life Sciences Companies Choose to Stay
Robert Evans
Chief Executive Officer
Wellcome Genome Campus
Keith Purdie
Senior Director of Development and Operations
Cambridge Science Park
Sarah Cary
Chief Development Officer
Imperial College London
Ruth Pardoe
Senior Asset Manager
Royal London Asset Management
Wet Lab, Dry Lab, Wrong Lab?: Are We Overbuilding, Underbuilding, or Just Building the Wrong Thing?
Barry Jessup
Managing Director
Socius
Mark Swetman
CEO
LS Estates
Simon Francis
Director of Estates & Facilities
LifeArc
Priya Shah
Director Life Sciences & Laboratories, UK
Merrick
Manisha Kulkarni
Director of Science & Technology
Bulb
Tim Fry
Business Leader | Science UKIMEA
ARUP UK
Three Tenants: Leasing for Pharma, Bioprocessing and the AI Cohort
Amy Hockley
Head of Innovation Leasing
British Land
Carl Williams
Director, UK Asset & Property Management
BioMed Realty
Henry Shearer
Head of Office and Investment, King’s Cross
King's Cross Group
Where Is the Next UK Lab Coming From and Who’s Investing?
Artem Korolev
Founder and CEO
Mission Street
Pete Wilder
Head of Property & Operations
Oxford Science Enterprises
Harry Pickering
Head of UK Investment
Pioneer Group
Matthew Weiner
Strategic Investment Adviser
The Crown Estate
Candice Blackwood
Partner,Head of Healthcare & Life Science Real Estate
CMS
Beyond the Golden Triangle: The Regional Manufacturing Bet
Brad Topps
Project Director, Sister Manchester & Chief Commercial Officer
Bruntwood Scitech
Kerry Walker
Managing Director
NETPark: North East Technology Park
Seb Loyn
Director of Planning & Development
YTL Developments
Lisa Hannon
Team Leader, Property
Scottish Enterprise
Presentation by McLaughlin & Harvey: The UK’s most developable life sciences locations – realising opportunities in the Golden Triangle and beyond
Alan Mackenzie
Life Sciences Bid Director
McLaughlin & Harvey
Jake Nunley
Cities Specialist
ING
The UK Life Sciences Sector Is Being Rebuilt From the Ground Up. Literally.
The UK life sciences sector is in the middle of a structural shift that comes along once in a generation. A government committing up to £1 billion in manufacturing and R&D investment. A biotech VC market recovering sharply, with £552 million raised in Q1 2026 alone, up 17% quarter-on-quarter. Clinical trial reform cutting setup times from 250 days to 122. And a wave of international M&A - from Eli Lilly to Amgen - validating UK-originated science assets at the highest levels.
Behind all of it is real estate. 3.7 million square feet of lab and innovation space under construction across London, Oxford and Cambridge. A £1 billion expansion at the London Cancer Hub. A £3 billion land deal at the Cambridge Biomedical Campus. And a pipeline of new clusters, from Whitechapel to White City, from Manchester to the Oxford-Cambridge Arc, transforming where UK science happens and who profits from it.
For CRE professionals, this is the moment. The deals are moving. The capital is flowing. The occupiers — biotechs, pharma, academia, NHS — are actively looking for space. The question is not whether this sector will grow. The question is who will be in the room when it does.
Five Questions This Summit Will Answer
- Where are the real investment opportunities in UK life sciences real estate — and which markets are already overheated?
- How is the government's £1 billion life sciences investment programme reshaping development economics — and how can developers and investors access it?
- What do life sciences occupiers actually need from their real estate in 2026 — and are developers building the right product?
- As M&A activity accelerates and UK biotech assets attract global acquirers, how does that reshape the occupier base — and what does it mean for lease risk?
- How are the UK's emerging clusters — Manchester, Birmingham, the Oxford-Cambridge Arc — closing the gap on London, and what does a winning regional life sciences strategy actually look like?
How You'll Do More Business
The UK life sciences real estate market is not a niche. It is the fastest-growing, most policy-backed, most internationally validated commercial real estate opportunity in Britain right now — and the window to establish position is compressing fast. The developers, investors, and advisors who build relationships in this sector today will be the ones executing the deals of the next decade. This summit exists to accelerate that process.
Featured Article:
UK biotech venture investment reaches five-year high at over £2bn in Q2
Bristol welcomes new scale-up lab space as the UK’s top deep tech city outside the Golden Triangle
Questions about your ticket purchase or interested in sponsoring? Reach out to customerservice@bisnow.com for customer support.
For questions, recommendations, comments, or press inquiries please email our VP of Production, Elizabeth Baker, at liz.baker@bisnow.com
To request disability-related accommodations, please contact lucrezia.manzo@bisnow.com no later than seven business days before the event.
Agenda
| Time | Activity |
|---|---|
|
8:00 AM
8:55 AM
|
Registration, Networking, and Breakfast
|
|
8:55 AM
9:00 AM
|
Welcome from Bisnow!
|
|
9:00 AM
9:40 AM
|
Where Is the Next UK Lab Coming From and Who’s Investing?
UK life sciences entered 2026 with returning venture capital, billion-dollar pharma acquisitions and half a billion pounds in government manufacturing grants. This panel asks where the next wave of lab demand actually comes from, what a market driven by acquisitions rather than IPOs means for the leases institutional investors are being asked to underwrite, and whether the assets being built today are the ones investors and occupiers are interested in. |
|
9:40 AM
9:50 AM
|
Presentation by McLaughlin & Harvey: The UK’s most developable life sciences locations – realising opportunities in the Golden Triangle and beyond
|
|
9:50 AM
10:30 AM
|
Three Tenants: Leasing for Pharma, Bioprocessing and the AI Cohort
AI companies are competing for the same buildings life sciences companies want. With BioMed Realty, British Land and King's Cross Central in the room, this panel asks who is actually signing leases right now and what it means when an AI firm outbids a biotech for a lab-spec floor. |
|
10:30 AM
10:50 AM
|
Networking Break!
|
|
10:50 AM
11:30 AM
|
Beyond the Golden Triangle: The Regional Manufacturing Bet
The big science and tech money is no longer just going to London, Oxford and Cambridge. This panel looks at why cities like Manchester, Bristol, and Sedgefield, as well as cities in Scotland, are attracting serious investment, and what it actually takes to build facilities for vaccines, tech innovation, defence spaces, research labs and more. Where will the next major facility land? |
|
11:30 AM
12:10 PM
|
Wet Lab, Dry Lab, Wrong Lab?: Are We Overbuilding, Underbuilding, or Just Building the Wrong Thing?
Wet labs cost up to five times more to fit out than dry labs, and AI computers are pushing power demands toward data centre territory. This panel asks whether developers can still build one building that works for all three tenant types, or whether the era of the flexible, all-purpose science and tech buildings are the future. |
|
12:12 PM
1:30 PM
|
Lunch and Networking Break!
|
|
1:30 PM
2:10 PM
|
Beyond the Building: Creating Campuses Where Life Sciences Companies Choose to Stay
The best life sciences campuses are communities, not just buildings. With the Wellcome Genome Campus, Cambridge Science Park, Imperial College London and Royal London Asset Management in the room, this panel asks what separates the campuses occupiers fight to get into from the ones they treat as a stepping stone. |
|
2:10 PM
3:30 PM
|
Closing Networking and Drinks!
|
Venue
Park Plaza London Westminster Bridge
200 Westminster Bridge Rd
London SE1 7UT
Function Room: Westminster Ballroom
Floor: - 1